Craig-Hallum raised the firm’s price target on Eton Pharmaceuticals (ETON) to $18 from $15 and keeps a Buy rating on the shares. The firm notes Eton has acquired Galzin, an FDA-approved oral treatment for Wilson Disease from Teva Pharmaceuticals (TEVA). The purchase includes U.S. rights to Galzin and European rights to the product, where it is marketed as Wilzin.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ETON:
- Eton Pharmaceuticals price target raised to $17 from $15 at H.C. Wainwright
- Eton Pharmaceuticals acquires Galzin
- Eton Pharmaceuticals announces final readout of PKU Golike clinical trial
- Eton Pharmaceuticals names Ipek Erdogan-Trinkaus as Chief Commercial Officer
- Eton Pharmaceuticals price target raised to $15 from $11 at H.C. Wainwright